EBS vs HIK.L
EBS: Emergent BioSolutions is a biopharmaceutical company providing critical medical countermeasures and life-saving naloxone treatments for global public health threats and emergencies. HIK.L: Hikma Pharmaceuticals is a global provider of generic, branded, and injectable medicines with a significant footprint in the US and MENA markets.
Side-by-side fundamentals
| Metric | EBS | HIK.L | Edge |
|---|---|---|---|
| Price | $6.81 | £16.46 | |
| Market cap | $349M | $4.5B | |
| Net margin | +7.1% | +12.2% | HIK.L higher |
| Gross margin | +30.3% | +43.0% | HIK.L higher |
| Operating margin FY2025, SEC XBRL | +13.5% | n/a | |
| ROE | +10.1% | +15.6% | HIK.L higher |
| ROA FY2025, SEC XBRL | +4.0% | n/a | |
| Debt / equity as of 2026-09-03 | 1.10 | n/a | |
| Revenue growth (YoY) as of 2026-09-03 | -29.9% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -12.7% | n/a | |
| Beta as of 2026-09-03 | 1.49 | n/a | |
| 1-year return | -31.1% | -9.8% | HIK.L higher |
Fundamentals: SEC XBRL company filings and annual report filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.